PYLARIFY TruVu (F18 PSMA) PDUFA Date (Lantheus Holdings)
FDA PDUFA decision date for PYLARIFY TruVu (F18 PSMA) is March 6, 2026. Developed by Lantheus Holdings. Indication: Prostate cancer PET imaging (recurrent/metastatic). Current status: Approved.
Indication
Prostate cancer PET imaging (recurrent/metastatic)
Regulatory details
- Company: Lantheus Holdings
- Therapeutic area: Oncology / Nuclear Medicine
- Application type: NDA
- Review type: Standard
- PDUFA date: 2026-03-06
- Outcome: Approved